These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 18482433)

  • 1. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies.
    Le Foll B; Forget B; Aubin HJ; Goldberg SR
    Addict Biol; 2008 Jun; 13(2):239-52. PubMed ID: 18482433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.
    Cahill K; Ussher M
    Cochrane Database Syst Rev; 2007 Oct; (4):CD005353. PubMed ID: 17943852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.
    Cahill K; Ussher M
    Cochrane Database Syst Rev; 2007 Jul; (3):CD005353. PubMed ID: 17636794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoid type 1 receptor antagonists for smoking cessation.
    Cahill K; Ussher MH
    Cochrane Database Syst Rev; 2011 Mar; 2011(3):CD005353. PubMed ID: 21412887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.
    Gueye AB; Pryslawsky Y; Trigo JM; Poulia N; Delis F; Antoniou K; Loureiro M; Laviolette SR; Vemuri K; Makriyannis A; Le Foll B
    Int J Neuropsychopharmacol; 2016 Dec; 19(12):. PubMed ID: 27493155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys.
    Schindler CW; Redhi GH; Vemuri K; Makriyannis A; Le Foll B; Bergman J; Goldberg SR; Justinova Z
    Neuropsychopharmacology; 2016 Aug; 41(9):2283-93. PubMed ID: 26888056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716).
    Cohen C; Perrault G; Griebel G; Soubrié P
    Neuropsychopharmacology; 2005 Jan; 30(1):145-55. PubMed ID: 15292905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration--comparison with CB(1) receptor blockade.
    Forget B; Coen KM; Le Foll B
    Psychopharmacology (Berl); 2009 Sep; 205(4):613-24. PubMed ID: 19484221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The endogenous cannabinoid system modulates nicotine reward and dependence.
    Merritt LL; Martin BR; Walters C; Lichtman AH; Damaj MI
    J Pharmacol Exp Ther; 2008 Aug; 326(2):483-92. PubMed ID: 18451315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rimonabant for treating tobacco dependence.
    Steinberg MB; Foulds J
    Vasc Health Risk Manag; 2007; 3(3):307-11. PubMed ID: 17703638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.
    Gelfand EV; Cannon CP
    Expert Opin Investig Drugs; 2006 Mar; 15(3):307-15. PubMed ID: 16503766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences.
    Le Foll B; Goldberg SR
    Neuroreport; 2004 Sep; 15(13):2139-43. PubMed ID: 15486497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data.
    Maccioni P; Colombo G; Carai MA
    CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):55-9. PubMed ID: 20201816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential involvement of the endocannabinoid system in short- and long-term expression of incentive learning supported by nicotine in rats.
    Forget B; Barthélémy S; Saurini F; Hamon M; Thiébot MH
    Psychopharmacology (Berl); 2006 Nov; 189(1):59-69. PubMed ID: 16969683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant.
    Justinova Z; Munzar P; Panlilio LV; Yasar S; Redhi GH; Tanda G; Goldberg SR
    Neuropsychopharmacology; 2008 Nov; 33(12):2870-7. PubMed ID: 18305459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain.
    Rigotti NA; Gonzales D; Dale LC; Lawrence D; Chang Y;
    Addiction; 2009 Feb; 104(2):266-76. PubMed ID: 19149823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking.
    Gamaleddin I; Wertheim C; Zhu AZ; Coen KM; Vemuri K; Makryannis A; Goldberg SR; Le Foll B
    Addict Biol; 2012 Jan; 17(1):47-61. PubMed ID: 21521420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats.
    Forget B; Hamon M; Thiébot MH
    Psychopharmacology (Berl); 2005 Oct; 181(4):722-34. PubMed ID: 15986197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol.
    López-Moreno JA; González-Cuevas G; Navarro M
    Neurobiol Dis; 2007 Feb; 25(2):274-83. PubMed ID: 17067804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
    McCollum L; Howlett AC; Mukhopadhyay S
    J Pharmacol Exp Ther; 2007 Jun; 321(3):930-7. PubMed ID: 17379772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.